Menarini Showcases ORSERDU® Advances at SABCS 2024 for ER+, HER2- mBC
Menarini Presents Data at SABCS 2024 Showcasing ORSERDU®’s Potential in ER+/HER2- Metastatic Breast Cancer The Menarini Group and its subsidiary, Stemline Therapeutics, are set to unveil new and expanded findings…
Exact Sciences Showcases Oncotype DX® and Genomic Research at SABCS 2024
Exact Sciences Highlights the Impact of Oncotype DX® and Genomic Insights at SABCS 2024 Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, will present a robust array of…
Bicycle Therapeutics to Present Zelenectide Pevedotin Data at SABCS 2024
Bicycle Therapeutics to Present Key Zelenectide Pevedotin Data at SABCS 2024 and Share Program Updates Bicycle Therapeutics plc (NASDAQ: BCYC), a company at the forefront of developing a novel therapeutic…
Enanta Pharmaceuticals Announces Fiscal Q4 and Full-Year 2024 Financial Results
Enanta Pharmaceuticals Delivers Key Updates on Virology and Immunology Programs While Reporting Fiscal Year 2024 Results Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company specializing in small molecule drugs…
Global Leaders Unite with Jeddah Commitments to Combat Antimicrobial Resistance
The Quadripartite organizations – the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO), and the World Organisation for…
Lebanon: A Conflict Devastating Health Care Systems
Since October 7, 2023, Lebanon has experienced an alarming escalation in attacks on health care, with nearly half of these assaults proving fatal to health workers or patients. As of…
Halozyme Withdraws Acquisition Proposal for Evotec Amid Lack of Engagement
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) at €11.00 per share in cash, representing a fully diluted equity value…
Can Cancer Be Treated by Activating the Body’s Defense System?
Cancer treatments are evolving, with increasing focus on using the body’s immune defenses to combat the disease. Reetta Virtakoivu, Senior Scientist at Orion, explains how immunotherapy works and why it…
FDA Approves Attruby™ (acoramidis) to Reduce Cardiovascular Risks in ATTR-CM Patients
BridgeBio Pharma, Inc. announced the FDA approval of Attruby™ (acoramidis), an oral stabilizer of transthyretin (TTR), for adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This treatment aims to reduce cardiovascular death…
Versant Ventures Launches Pep2Tango Therapeutics Inc
Versant Ventures has announced the launch of Pep2Tango Therapeutics Inc., a new startup focused on next-generation weight loss treatments. The company will use funds from a significant, undisclosed investment round…
Population Health Research Institute Celebrates 25 Years of Advancing Global Health Research and Innovation
Population Health Research Institute (PHRI), a joint initiative of McMaster University and Hamilton Health Sciences, is celebrating its 25th anniversary as a global leader in health research. Over the past…
ReAlta Life Sciences Appoints Lewis T. Williams, M.D., Ph.D. as Chairman
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on rebalancing the inflammatory response to treat rare and acute inflammatory diseases, has announced the appointment of…